Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Top-Institutions - MDSpire

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • By

  • Matthias Augustin

  • Paul-Gunther Sator

  • Ralph von Kiedrowski

  • Dimitris Rigopoulos

  • Marco Romanelli

  • Pierre-Dominique Ghislain

  • Tiago Torres

  • Dimitrios Ioannides

  • Cynthia Vizcaya

  • Andreas Clemens

  • Weibin Bao

  • Christelle C. Pieterse

  • Barbara Schulz

  • Piotr Jagiello

  • Curdin Conrad

  • April 2, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    National Psoriasis Foundation Research Center at Northwestern University
    National Psoriasis Foundation Research Center at Northwestern University

    Chicago, IL

    Key Differentiators

    • Dermatology
    • Psoriasis Research
    • Clinical Trials

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Medicine

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Stockholm County

    Key Differentiators

    • Dermatology
    • Clinical Epidemiology
    • Immunology

  • #5

    St. John’s Institute of Dermatology, King’s College London
    St. John’s Institute of Dermatology, King’s College London

    London, England

    Key Differentiators

    • Dermatology
    • Psoriasis Research
    • Clinical Trials

Original Source(s)

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad

  • April 2, 2026

Related Content

Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.